- Active not recruitingPHASE3
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, selpercatinib, to see if it can stop lung cancer from coming back after surgery or radiation. It's for people with a specific type of non-small cell lung cancer.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This study looks at a new medicine called Selpercatinib for children and young people (ages 6 months to 21 years) with certain advanced solid tumours or brain tumours. It's for those whose tumours have a specific genetic change (called RET alteration).
For: Medullary Thyroid Cancer · Infantile Myofibromatosis · Infantile FibrosarcomaUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
This study is testing a new drug called selpercatinib for a type of thyroid cancer that has spread or can't be removed by surgery. It wants to see if this new drug is safer and works better than current treatments for people with a specific gene change (RET mutation).
For: Medullary Thyroid CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
This study looks at a new drug, selpercatinib, for people with a type of lung cancer that has spread. It compares this new drug to standard treatments to see if it's safe and works well for their specific cancer type.
For: Non-Small Cell Lung CancerArgentina · Australia · Belgium